Cargando…

Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla™ EGFR Testing Platform

Introduction: Patients with advanced-stage non-small cell lung cancer (NSCLC) may benefit from a short time-to-treatment (TTT). Predictive biomarker testing is performed prior to treatment, as recommended by various international expert consensus bodies. Genetic testing is more time-intensive than i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banyi, Norbert, Alex, Deepu, Hughesman, Curtis, McNeil, Kelly, N. Ionescu, Diana, Ma, Carmen, Yip, Stephen, Melosky, Barbara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600153/ https://www.ncbi.nlm.nih.gov/pubmed/36290901 http://dx.doi.org/10.3390/curroncol29100624

Ejemplares similares

Testing EGFR with Idylla on Cytological Specimens of Lung Cancer: A Review
por: Caputo, Alessandro, et al.
Publicado: (2021)

EGFR circulating tumour DNA testing: identification of predictors of ctDNA detection and implications for survival outcomes
por: Pender, Alexandra, et al.
Publicado: (2020)

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
por: Offerman, Saskia, et al.
Publicado: (2021)

A Case of ALK-Rearranged Combined Lung Adenocarcinoma and Neuroendocrine Carcinoma with Diffuse Bone Metastasis and Partial Response to Alectinib
por: Lim, Chloe A., et al.
Publicado: (2022)

Not enough can be enough: feasibility of the Idylla EGFR mutation test when reuse of stained tissue slides is the only option available
por: Ercolani, Cristiana, et al.
Publicado: (2022)

Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer
por: Delgado-García, Mercedes, et al.
Publicado: (2020)

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
por: Suda, Kenichi, et al.
Publicado: (2023)

Evaluation of the Idylla ctEGFR mutation assay to detect EGFR mutations in plasma from patients with non-small cell lung cancers
por: Gilson, Pauline, et al.
Publicado: (2021)

First-line osimertinib for patients with EGFR-mutated advanced non-small cell lung cancer: efficacy and safety during the COVID-19 pandemic
por: Lakkunarajah, Suganija, et al.
Publicado: (2023)

Contribution of the Idylla(TM) System to Improving the Therapeutic Care of Patients with NSCLC through Early Screening of EGFR Mutations
por: Petiteau, Constance, et al.
Publicado: (2021)

Review of EGFR TKIs in Metastatic NSCLC, Including Ongoing Trials
por: Melosky, Barbara
Publicado: (2014)

Diagnostic performance of Idylla MSI test in colorectal cancer biopsies
por: Ukkola, Iiris, et al.
Publicado: (2023)

Adoring ADAURA: can we cure lung cancer that harbors an EGFR mutation?
por: Melosky, Barbara
Publicado: (2023)

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform
por: Bisschop, Cornelis, et al.
Publicado: (2018)

Management of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR–TKIs
por: Melosky, Barbara, et al.
Publicado: (2014)

Real-World Clinical Outcomes for Patients with EGFR and HER2 Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer
por: Li, Kelly, et al.
Publicado: (2023)

Ultra-rapid Idylla™ EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer
por: Qiu, Tian, et al.
Publicado: (2023)

Advanced Non-small Cell Lung Cancer: EGFR Mutation Analysis Using Pyrosequencing and the Fully Automated qPCR-Based Idylla(TM) System
por: Boustany, Youssra, et al.
Publicado: (2023)

EGFR Testing Patterns and Detection of EGFR Exon 20 Insertions in the United States
por: Lin, Huamao M., et al.
Publicado: (2022)

Optimization of EGFR mutation detection by the fully-automated qPCR-based Idylla system on tumor tissue from patients with non-small cell lung cancer
por: Ilie, Marius, et al.
Publicado: (2017)

Performance of Idylla(™) RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer
por: Makutani, Yusuke, et al.
Publicado: (2022)

Efficient Lung Cancer Molecular Diagnostics by Combining Next Generation Sequencing with Reflex Idylla Genefusion Assay Testing
por: Nkosi, Dingani, et al.
Publicado: (2023)

Fully automated diagnosis of MERS-CoV infection in respiratory specimen on the IdyllaTM MDx Platform
por: Trost, N., et al.
Publicado: (2016)

Comparison of next‐generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations
por: Murakami, Shuji, et al.
Publicado: (2022)

KRAS detection on archival cytological smears by the novel fully automated polymerase chain reaction-based Idylla mutation test
por: De Luca, Caterina, et al.
Publicado: (2017)

Comparison of cross-platform technologies for EGFR T790M testing in patients with non-small cell lung cancer
por: Li, Xuefei, et al.
Publicado: (2017)

Comprehensive cross‐platform comparison of methods for non‐invasive EGFR mutation testing: results of the RING observational trial
por: Romero, Atocha, et al.
Publicado: (2020)

Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients
por: Pugh, Trevor J, et al.
Publicado: (2007)

Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test
por: Durślewicz, Justyna, et al.
Publicado: (2020)

Utility of Select Gene Mutation Detection in Tumors by the Idylla Rapid Multiplex PCR Platform in Comparison to Next-Generation Sequencing
por: Nkosi, Dingani, et al.
Publicado: (2022)

The Use of a Two-Tiered Testing Strategy for the Simultaneous Detection of Small EGFR Mutations and EGFR Amplification in Lung Cancer
por: Lewandowska, Marzena Anna, et al.
Publicado: (2015)

Optimizing molecular residual disease detection using liquid biopsy postoperatively in early stage lung cancer
por: McGuire, Anna L, et al.
Publicado: (2020)

Management of skin rash during egfr-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations
por: Melosky, B., et al.
Publicado: (2009)

Clinical performance evaluation of the Idylla NRAS-BRAF mutation test on retrospectively collected formalin-fixed paraffin-embedded colorectal cancer tissue
por: Johnston, Louise, et al.
Publicado: (2018)

Detection of microsatellite instability with Idylla MSI assay in colorectal and endometrial cancer
por: Ukkola, Iiris, et al.
Publicado: (2021)

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples
por: Vivancos, Ana, et al.
Publicado: (2019)

A CRISPR Test for Rapidly and Sensitively Detecting Circulating EGFR Mutations
por: Tsou, Jen-Hui, et al.
Publicado: (2020)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

Evaluation of Sample Pooling for SARS-CoV-2 Detection in Nasopharyngeal Swab and Saliva Samples with the Idylla SARS-CoV-2 Test
por: Hofman, Paul, et al.
Publicado: (2021)

Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions
por: González de Aledo-Castillo, José Manuel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c4f74v4j31jbfelj3m85ni7uaq